Salud financiera de hoja de balance de Treace Medical Concepts

Salud financiera controles de criterios 5/6

Treace Medical Concepts tiene un patrimonio de los accionistas total de $137.9M y una deuda total de $53.0M, lo que sitúa su ratio deuda-patrimonio en 38.4%. Sus activos y pasivos totales son $251.9M y $114.0M respectivamente.

Información clave

38.4%

Ratio deuda-patrimonio

US$53.01m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$123.20m
Patrimonio	US$137.94m
Total pasivo	US$113.97m
Activos totales	US$251.91m

Actualizaciones recientes sobre salud financiera

Does Treace Medical Concepts (NASDAQ:TMCI) Have A Healthy Balance Sheet?

Feb 09

Recent updates

Market Still Lacking Some Conviction On Treace Medical Concepts, Inc. (NASDAQ:TMCI)

Apr 05

Does Treace Medical Concepts (NASDAQ:TMCI) Have A Healthy Balance Sheet?

Feb 09

Why Investors Shouldn't Be Surprised By Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) 31% Share Price Surge

Jan 04

Market Cool On Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) Revenues Pushing Shares 46% Lower

Nov 11

Analysts Are Updating Their Treace Medical Concepts, Inc. (NASDAQ:TMCI) Estimates After Its Second-Quarter Results

Aug 13

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($198.4M) de TMCI superan a sus pasivos a corto plazo ($45.0M).

Pasivo a largo plazo: Los activos a corto plazo de TMCI ($198.4M) superan a sus pasivos a largo plazo ($68.9M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: TMCI tiene más efectivo que su deuda total.

Reducción de la deuda: No se dispone de datos suficientes para determinar si el ratio deuda-patrimonio de TMCI se ha reducido en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: TMCI tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: TMCI dispone de suficiente cash runway para más de 3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 51.7% cada año

Salud financiera de hoja de balance de Treace Medical Concepts

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Does Treace Medical Concepts (NASDAQ:TMCI) Have A Healthy Balance Sheet?

Recent updates

Treace Medical Concepts, Inc. to Report Q1, 2024 Results on May 07, 2024

Market Still Lacking Some Conviction On Treace Medical Concepts, Inc. (NASDAQ:TMCI)

Treace Medical Concepts, Inc., Annual General Meeting, May 21, 2024

Consensus EPS estimates fall by 61%

Price target increased by 8.8% to US$15.86

Treace Medical Concepts, Inc. Provides Revenue Guidance for the Year 2024

Full year 2023 earnings: EPS misses analyst expectations

Does Treace Medical Concepts (NASDAQ:TMCI) Have A Healthy Balance Sheet?

Treace Medical Concepts, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Treace Medical Concepts, Inc. Announces Three-Year Interim Data from Its Align3d™? Post-Market Study Supporting the Use of the Lapiplasty Procedure for Treating Bunions

Why Investors Shouldn't Be Surprised By Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) 31% Share Price Surge

Price target increased by 9.7% to US$14.57

Treace Medical Concepts, Inc. Revises Revenue Guidance for the Year 2023

Market Cool On Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) Revenues Pushing Shares 46% Lower

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Treace Medical Concepts, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Price target decreased by 8.7% to US$25.43

Price target decreased by 11% to US$26.00

New minor risk - Share price stability

Treace Medical Concepts, Inc. Highlights New Product Innovations and Updated Align3d Clinical Study Data At the American Orthopaedic Foot & Ankle Society Annual Meeting 2023

Treace Medical Concepts, Inc. Announces Limited Market Release of New Complementary Technologies for Treating Bunions and Related Procedures

Treace Medical Concepts, Inc. Appoints Nathan Minnich as Senior Vice President, Marketing

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Treace Medical Concepts, Inc. Revises Revenue Guidance for the Year 2023

Now 26% undervalued after recent price drop

Treace Medical Concepts, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Treace Medical Concepts, Inc. Appoints Julie Dewey as Chief Communications and Investor Relations Officer, Effective July 17, 2023

Now 22% undervalued after recent price drop

Treace Medical Concepts, Inc. acquired Certain assets of MIOS Marketing, LLC dba RedPoint Medical 3D for $30 million.

Insider recently sold US$29m worth of stock

Independent Director notifies of intention to sell stock

Treace Medical Concepts, Inc. acquired Certain assets of MIOS Marketing, LLC dba RedPoint Medical 3D for $30 million.

Chief Innovation Officer exercised options and sold US$633k worth of stock

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Treace Medical Concepts, Inc. Raises Revenue Guidance for Full Year 2023

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Chief Human Resources Officer notifies of intention to sell stock

Chief Human Resources Officer notifies of intention to sell stock

CEO, Founder & Director recently sold US$51k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Chief Innovation Officer exercised options and sold US$540k worth of stock

Treace Medical Concepts, Inc. Presents Updated ALIGN3D Interim Data and New Product Innovations at 2023 ACFAS Annual Conference

Treace Medical Concepts, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Independent Director recently sold US$480k worth of stock

Treace Medical Concepts, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Chief Human Resources Officer exercised options and sold US$82k worth of stock

Treace Receives FDA 510(k) Clearance for SpeedPlate(TM) Rapid Compression Implant Technology

Treace Medical Concepts, Inc. Receives FDA 510(K) Clearance for Speedplate Rapid Compression Implant Technology

Treace Medical Concepts, Inc. Announces First Patient Treated in MTA3D™ Adductoplasty® Clinical Study

CEO, Founder & Director recently bought US$217k worth of stock

Senior Vice President of Marketing exercised options and sold US$604k worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Treace Medical Concepts, Inc. Revises Revenue Guidance for the Full Year 2022

Independent Director recently sold US$2.2m worth of stock

Treace Medical Concepts, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Independent Director notifies of intention to sell stock

Treace Medical Concepts, Inc. Announces the Appointment of Lance E. Berry and Jane E. Kiernan to Its Board of Directors, Effective October 1, 2022

Price target increased to US$28.75

Treace Medical Concepts, Inc. Announces Update ALIGN3D Data At the 2022 AOFAS Annual Meeting

Independent Director notifies of intention to sell stock

CEO, Founder & Director recently bought US$534k worth of stock

Consensus forecasts updated

Analysts Are Updating Their Treace Medical Concepts, Inc. (NASDAQ:TMCI) Estimates After Its Second-Quarter Results

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Treace Medical Concepts, Inc. Revises Revenue Guidance for the Full Year 2022

Treace Medical Concepts, Inc. Announces Full Commercial Release of New Technologies for Bunion and Related Midfoot Surgery

Treace Medical Concepts, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Price target decreased to US$25.50

Chief Financial Officer recently bought US$98k worth of stock

Price target decreased to US$28.60

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Treace Medical Announces Peer-Reviewed Publication of ALIGN3D Multicenter Prospective Clinical Data

No longer forecast to breakeven